Half-year report · HY
6960.TEDINET S100X29Y
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥139.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥64.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥10.7bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.9bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥26.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥11.0bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥11.4bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥18.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥7.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥212.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥221.3bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥204.8bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥39.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥178.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥181.7bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥172.0bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥65.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥72.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥60.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥67.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥61.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.2bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥16.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥33.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥9.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥13.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥273.47 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥645.41 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥267.34 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 83.6% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Consumables And Other Productsreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.9bn |
| Consumables And Other Productsreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.9bn |
| Consumables And Other Productsreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2.7bn |
| Medical Treatment Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.3bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥31.3bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Patient Monitoring Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥574m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥11.1bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥11.1bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥64.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥10.7bn |
| Consumables And Other Productsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| Consumables And Other Productsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥17.8bn |
| Consumables And Other Productsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Medical Treatment Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Medical Treatment Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Medical Treatment Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Patient Monitoring Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| Patient Monitoring Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.1bn |
| Patient Monitoring Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥658m |
| Physiological Diagnostic Equipmentreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Physiological Diagnostic Equipmentreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Physiological Diagnostic Equipmentreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥64.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥10.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 532
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents | Prior1InterimInstant | 61171000000 | JPY |
| Cash and cash equivalents | InterimInstant | 60735000000 | JPY |
| Discounted export bill obligation | Prior1YearInstant | － | JPY |
| Discounted export bill obligation | InterimInstant | 20000000 | JPY |
| Directors compensations salaries and allowances sga | Prior1InterimDuration | 8841000000 | JPY |
| Directors compensations salaries and allowances sga | InterimDuration | 9133000000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 2377000000 | JPY |
| Provision for bonuses sga | InterimDuration | 2486000000 | JPY |
| Provision for directors retirement benefits sga | Prior1InterimDuration | 19000000 | JPY |
| Provision for directors retirement benefits sga | InterimDuration | 19000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 453000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 410000000 | JPY |
| Provision for directors bonuses sga | Prior1InterimDuration | 258000000 | JPY |
| Provision for directors bonuses sga | InterimDuration | 248000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 11888000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 4136000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 30500000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 17789000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 64314000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 64314000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 11888000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 4136000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 30500000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 17789000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 64314000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1InterimDuration | 64314000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 1761000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 658000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 5612000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 2622000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10654000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1InterimDuration | 10654000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | 11070000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02304-000PatientMonitoringEquipmentReportableSegmentsMember | 3497000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02304-000MedicalTreatmentEquipmentReportableSegmentsMember | 31338000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02304-000ConsumablesAndOtherProductsReportableSegmentsMember | 18899000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 64807000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 64807000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02304-000PhysiologicalDiagnosticEquipmentReportableSegmentsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |